/
We are a clinical-stage C lustered R egularly I nterspaced S hort P alindromic R epeats ( CRISPR ) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Our genome-editing platform is based on our novel chRDNA ( C RISPR h ybrid R NA- DNA , or chRDNA, pronounced chardonnay ) genome-editing technology, which enables more …
The business is unprofitable at the operating level (-1329.37% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 11.7% YoY with margins expanding 337.8pp.
ROIC dropped from -39.00% to -54.66%, capital efficiency is deteriorating. Negative free cash flow of -$112M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$11M
▲ +11.7% YoY
Net Income (TTM)
-$133M
▲ +0.7% YoY
Op. Margin
-1175.68%
▲ +337.8pp YoY
ROIC
-65.27%
▼ -15.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$102M
▲ +21.5% YoY
Op. Cash Flow (TTM)
-$101M
▲ +19.7% YoY
Net Debt
-$91M
Net Cash Position
Cash & Equiv.
$118M
5Y CAGR: -2.0%
Continue Research